You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

R-CHOP-21

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma Trial in Italy (Treatment plan)

Completed
  • Diffuse Large B Cell Lymphoma
  • Treatment plan
  • Milano, MI, Italy
  • +18 more
Feb 15, 2022

Lymphoma, B-Cell Trial in Worldwide (CC-220, Rituximab, Cyclophosphamide)

Recruiting
  • Lymphoma, B-Cell
  • Scottsdale, Arizona
  • +26 more
Jul 1, 2022

Follicular Lymphoma (FL) Trial (biological, drug, other)

Not yet recruiting
  • Follicular Lymphoma (FL)
  • Tisagenlecleucel
  • +4 more
  • (no location specified)
May 24, 2023

Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

Not yet recruiting
  • Advanced Diffuse Large B-Cell Lymphoma
  • +2 more
  • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
  • Radiotherapy beyond standard R-CHOP Chemotherapy
  • (no location specified)
May 24, 2023

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia Trial in Germany, Italy, Spain

Completed
  • Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
  • Aurich, Germany
  • +59 more
Jun 6, 2022

Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Orelabrutinib + R-CHOP
  • Placebo + R-CHOP
  • Shanghai, Shanghai, China
    Shanghai Ruijing Hospital
Nov 28, 2022

The First Affiliated Hospital of Nanchang University Trial in Nanchang, Jinan (Orelabrutinib+R-CHOP)

Recruiting
  • The First Affiliated Hospital of Nanchang University
  • Nanchang, Jiangxi, China
  • +1 more
Jul 3, 2023

Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Shenyang, Liaoning, China
    Xing Xiaojing
Jun 1, 2023

Lymphomas Non-Hodgkin's B-Cell Trial in Ballarat, Box Hill, Heidelberg (Avelumab)

Active, not recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • Ballarat, Victoria, Australia
  • +2 more
Jan 30, 2023

Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
Dec 1, 2022

Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • (no location specified)
Jun 28, 2023

Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

Not yet recruiting
  • Marginal Zone Lymphoma
  • Mosunetuzumab + Lenalidomide
  • +3 more
  • (no location specified)
Aug 16, 2023

Richter Syndrome Trial in United States (Venetoclax, DA-EPOCH-R, R-CHOP)

Recruiting
  • Richter Syndrome
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (Durvalumab, Rituximab, Doxorubicin)

Completed
Has Results
  • Lymphoma, Large B-Cell, Diffuse
  • Gilbert, Arizona
  • +18 more
Aug 19, 2022

EBV-Positive DLBCL, Nos Trial in Guangzhou, Shanghai (Selinexor, R-CHOP Protocol)

Recruiting
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
  • Guangzhou, Guangdong, China
  • +1 more
Nov 10, 2022

DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Aug 10, 2022

Diffuse Large B Cell Lymphoma Trial in Colchester, Canterbury, Nottingham (R-CHOP, R-CHOP + acalabrutinib)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Colchester, Essex, United Kingdom
  • +32 more
Oct 25, 2022

Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Apr 24, 2022

Diffuse B-Cell Lymphoma Trial in Worldwide (Avadomide (CC-122), Rituximab, Cyclophosphamide 750mg/m2 by IV infusion)

Completed
  • Diffuse B-Cell Lymphoma
  • Avadomide (CC-122)
  • +4 more
  • Washington, District of Columbia
  • +14 more
Apr 28, 2021

Diffuse Large B Cell Lymphoma Trial in Wuhan (Zanubrutinib plus RCHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib plus RCHOP
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 16, 2023

Diffuse Large B Cell Lymphoma Trial in Wenzhou (Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Wenzhou, Zhejiang, China
    First Affiliated Hospital of Wenzhou Medical University
Jun 20, 2022

Non Hodgkin Lymphoma Trial in United Kingdom (R-CHOP + acalabrutinib)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • R-CHOP + acalabrutinib
  • Southampton, Hampshire, United Kingdom
  • +6 more
Oct 26, 2022

Mantle Cell Lymphoma Trial in Canada (Acalabrutinib, R-CHOP chemo)

Recruiting
  • Mantle Cell Lymphoma
  • Vancouver, British Columbia, Canada
  • +3 more
Mar 17, 2022

Mantle Cell Lymphoma Trial in Beijing

Recruiting
  • Mantle Cell Lymphoma
    • Beijing, Beijing, China
      Hongmei Third Jing
    Jun 20, 2022

    Diffuse Large B-cell Lymphoma(DLBCL) Trial in Shanghai (Zanubrutinib + R-CHOP)

    Recruiting
    • Diffuse Large B-cell Lymphoma(DLBCL)
    • Zanubrutinib + R-CHOP
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 10, 2022